This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Neutrophil-membrane-coated nanoparticles loaded with FGF21 reduced heart damage after ischemia-reperfusion in mice by targeting inflamed cardiac tissue.
Why it matters
FGF21 is a metabolic regulator (like GLP-1 drugs) that protects the heart. Wrapping it in neutrophil membranes helps it reach damaged heart tissue more effectively.
The numbers in context
Neutrophil-membrane coated liposomal NPs with FGF21; tested in mouse ischemia-reperfusion model; improved cardiac outcomes vs uncoated NPs.
How the study worked
Nanoparticle fabrication, neutrophil membrane coating, characterization, and in vivo testing in mouse I/R injury model.
Who was studied
Mice with ischemia-reperfusion cardiac injury
What this study cannot tell us
Mouse model. Complex manufacturing process. Long-term safety of neutrophil-coated particles unknown. FGF21 may have off-target effects.
Read the original research
Enhanced FGF21 Delivery via Neutrophil-Membrane-Coated Nanoparticles Improves Therapeutic Efficacy for Myocardial Ischemia-Reperfusion Injury.
Nanomaterials (Basel, Switzerland), 15(5)
Citation
Rao, Zhiheng; Tang, Yuli; Zhu, Jiamei; Lu, Zhenzhen; Chen, Zhichao; Wang, Jiaojiao; Bao, Yuxuan; Mukondiwa, Alan Vengai; Wang, Cong; Wang, Xiaojie; Luo, Yongde; Li, Xiaokun. (2025). Enhanced FGF21 Delivery via Neutrophil-Membrane-Coated Nanoparticles Improves Therapeutic Efficacy for Myocardial Ischemia-Reperfusion Injury.. Nanomaterials (Basel, Switzerland), 15(5). https://doi.org/10.3390/nano15050346